The role of lncRNAs in ischemic stroke

Chen, Jian; Liu, Pinyi; Dong, Xiaohong; Jin, Jiali; Xu, Yun

doi:10.1016/j.neuint.2021.105019

Cited by 13 publications

(6 citation statements)

References 98 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…lncRNAs have been demonstrated to be widely expressed in the brain, and be involved in the physiological and pathophysiological processes, such as neural development, cerebral ischemic injury, and neurodegeneration. Also, it was shown to mediate pathogenic processes, including neuroinflammation and apoptosis, oxidative stress, and excitotoxicity, which are closely correlated with cerebral ischemia and post-stroke recovery [3,24]. For example, lncRNA MIAT can promote the apoptosis and autophagy of neural cells, which further enhance the malignant development of ischemic stroke [6].…”

Section: Discussionmentioning

confidence: 99%

“…To improve the diagnosis and therapy efficiency of AIS, an increasing number of research have been devoted to the identification of biomarkers, which indicate the onset and development of patients' illness. Among those studies, non-coding RNAs (ncRNAs) have been extensively investigated in AIS [3,24]. lncRNA NORAD (NORAD) is a long non-coding RNA that has been reported to play roles in various human diseases.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Upregulated lncRNA NORAD can diagnose acute cerebral ischemic stroke patients and predict poor prognosis

Li¹,

Li²,

Xu³

et al. 2023

View full text Add to dashboard Cite

Introduction: Acute cerebral ischemic stroke (AIS) dramatically influences patients' quality of life. lncRNA NORAD (NORAD) has been studied in cerebrovascular diseases, which are potential risk factors for AIS. The specific significance of NORAD is unclear. This study aimed to assess the role of NORAD in AIS, and to provide therapeutic value for its' treatment. Material and methods: A total of 103 AIS patients and 95 healthy individuals (control) were enrolled into this study. Expression level of NORAD in the plasma of all participants was analyzed by PCR. Diagnostic potential of NORAD in AIS was evaluated by ROC analysis, while Kaplan-Meier and Cox regression analyses were conducted to assess its' prognostic value in AIS.Results: A significantly increased level of NORAD was observed in AIS patients compared with healthy individuals. The upregulation of NORAD could dramatically discriminate AIS patients from healthy individuals with high sensitivity (81.60%) and specificity (88.40%). NORAD was positively correlated with patients' high-sensitivity C-reactive protein (hs CRP, r = 0.796), matrix metalloproteinase-9 (MMP9, r = 0.757), and NIHSS scores (r = 0.840), and negatively related to pc-ASPECTS scores (r = -0.607). Moreover, NORAD upregulation was associated with patients' unfavorable prognosis and served as an independent prognostic biomarker, together with NIHSS and pc-ASPECTS scores of AIS patients. Conclusions: NORAD was upregulated in AIS, which can discriminate AIS patients, and was closely correlated with severe development and poor prognosis of patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Upregulated lncRNA NORAD can diagnose acute cerebral ischemic stroke patients and predict poor prognosis

Li¹,

Li²,

Xu³

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Patients with coronary artery disease (CAD) associate low serum levels of miRNAs secondary to their sequestration in atherosclerotic plaques, which mediate neoformation processes and maintain proinflammatory status [102]. Special attention has also been paid in recent studies to noncoding RNAs (ncRNAs) which are involved in several processes such as atherosclerosis, angiogenesis, neuroinflammation, or apoptosis, but their clinical applicability is currently limited [103][104][105]. Zhao et al [103] concluded that ncRNAs are potential biomarkers for early diagnosis of ischemic stroke similar to miR-107 and miR-135b [106,107].…”

Section: Biomarkers Of Destabilization Of Atherosclerotic Plaque-micr...mentioning

confidence: 99%

Novel Biomarkers of Atherosclerotic Vascular Disease—Latest Insights in the Research Field

Adam¹,

Șalaru

Prisacariu

et al. 2022

IJMS

View full text Add to dashboard Cite

The atherosclerotic vascular disease is a cardiovascular continuum in which the main role is attributed to atherosclerosis, from its appearance to its associated complications. The increasing prevalence of cardiovascular risk factors, population ageing, and burden on both the economy and the healthcare system have led to the development of new diagnostic and therapeutic strategies in the field. The better understanding or discovery of new pathophysiological mechanisms and molecules modulating various signaling pathways involved in atherosclerosis have led to the development of potential new biomarkers, with key role in early, subclinical diagnosis. The evolution of technological processes in medicine has shifted the attention of researchers from the profiling of classical risk factors to the identification of new biomarkers such as midregional pro-adrenomedullin, midkine, stromelysin-2, pentraxin 3, inflammasomes, or endothelial cell-derived extracellular vesicles. These molecules are seen as future therapeutic targets associated with decreased morbidity and mortality through early diagnosis of atherosclerotic lesions and future research directions.

show abstract

“…Stroke is one of the major diseases that cause death and disability in the world, [ 1 ] it not only seriously threatens people’s health, but also causes a huge economic burden to society. [ 2 , 3 ] The World Health Organization reports that about 5.5 million people die from stroke each year, of which Ischemic stroke (IS) accounts for 87%.…”

Section: Introductionmentioning

confidence: 99%

Multi-target mechanism of Naoshuantong capsule for treatment of Ischemic stroke based on network pharmacology and molecular docking

Yang,

Yan,

et al. 2023

Medicine

View full text Add to dashboard Cite

Background: Naoshuantong capsule (NST capsule) is a classic Chinese patent medicine, which can treat ischemic stroke (IS) and has good clinical efficacy. However, its pharmacological mechanism remains to be further explored in the treatment of IS. Methods: The bio-active components and potential targets of NST Capsules were obtained by ETCM and TCMSP databases. In addition, the related targets of IS were collected by Genecard, OMIM, DrugBank, TTD and DisGeNET databases. NST-IS common target was obtained by Venn platform. PPI network of NST-IS common target and the composition - target network diagram of NST Capsule were constructed by Cytoscape3.8.1. Finally, AutoDock was used for molecular docking. Results: 265 targets were predicted from 32 active compounds in NST Capsule, 109 common targets were identified between NST Capsule and IS. The top 10 key targets of PPI network were ALB, TNF, TP53, VEGFA, CASP3, MYC, etc. Enrichment analysis showed that NST capsules treated IS mainly through lipid and atherosclerosis, fluid shear stress and atherosclerosis signaling pathways. Conclusion: Through the methods of network pharmacology and molecular docking, this study clarified that NST capsules play a role in the treatment of IS, which is multi-target, multi-channel and multi-component regulation. This study further explored the pharmacological mechanism of NST capsule in the treatment of IS, which can provide some references for the subsequent research in the pharmacological mechanism of NST capsule.

show abstract

The role of lncRNAs in ischemic stroke

Cited by 13 publications

References 98 publications

Upregulated lncRNA NORAD can diagnose acute cerebral ischemic stroke patients and predict poor prognosis

Upregulated lncRNA NORAD can diagnose acute cerebral ischemic stroke patients and predict poor prognosis

Novel Biomarkers of Atherosclerotic Vascular Disease—Latest Insights in the Research Field

Multi-target mechanism of Naoshuantong capsule for treatment of Ischemic stroke based on network pharmacology and molecular docking

Contact Info

Product

Resources

About